Clementia Pharmaceuticals (CMTA) vs. Its Competitors Head to Head Contrast

Clementia Pharmaceuticals (NASDAQ: CMTA) is one of 293 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Clementia Pharmaceuticals to similar companies based on the strength of its analyst recommendations, institutional ownership, dividends, earnings, valuation, profitability and risk.

Analyst Recommendations

This is a summary of recent ratings and price targets for Clementia Pharmaceuticals and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clementia Pharmaceuticals 0 0 4 0 3.00
Clementia Pharmaceuticals Competitors 1218 3588 12109 251 2.66

Clementia Pharmaceuticals presently has a consensus price target of $27.00, suggesting a potential upside of 68.01%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 38.56%. Given Clementia Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Clementia Pharmaceuticals is more favorable than its competitors.

Valuation and Earnings

This table compares Clementia Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Clementia Pharmaceuticals N/A -$57.51 million -3.14
Clementia Pharmaceuticals Competitors $293.65 million $35.70 million 71.11

Clementia Pharmaceuticals’ competitors have higher revenue and earnings than Clementia Pharmaceuticals. Clementia Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

68.4% of Clementia Pharmaceuticals shares are held by institutional investors. Comparatively, 48.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.3% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


This table compares Clementia Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Clementia Pharmaceuticals N/A N/A -211.59%
Clementia Pharmaceuticals Competitors -5,409.58% -155.65% -34.34%

Clementia Pharmaceuticals Company Profile

Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models. It is developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO). Its programs focus on diseases involving tissue transformation via retinoic acid receptors (RARs). The Company also has an eye drop formulation of palovarotene that can potently increase tear production and decrease corneal damage.

Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply